Biomarkers for Risk and Outcomes of Type 2 Diabetes: A Discovery and Validation Approach in Australian and Chinese subjects

2 型糖尿病风险和结果的生物标志物：在澳大利亚和中国受试者中的发现和验证方法

• 批准号: nhmrc : 1113592
• 负责人: A/Pr Anand Hardikar
• 金额: $ 41.25万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Targeted Calls
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/biomarkers-risk-outcomes-chinese-subjects/663263
• 关键词: Biomarkers; Risk; Outcomes; Type; Diabetes

The aim is to make better outcomes for people with Type 2 diabetes in Australia and China, by exploring various tests to improve prediction of diabetes progression, complication risk and treatment response. The team has data and samples from the Fenofibrate Intervention and Event Lowering in Diabetes Trial and from the Shanghai Diabetes Study. This approach is very time and cost-effective. We will also study animal models to understand mechanisms of diabetes damage, and test new treatments.

其目的是通过探索各种测试来改善对糖尿病进展、并发症风险和治疗反应的预测，为澳大利亚和中国的2型糖尿病患者提供更好的结果。该团队拥有来自非诺贝特干预和降低糖尿病事件试验以及上海糖尿病研究的数据和样本。这种方法非常省时，成本效益高。我们还将研究动物模型，以了解糖尿病损害的机制，并测试新的治疗方法。